Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of ABBV-154 in Healthy Subjects
NCT05556226Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2022
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ABBV-154 in polymyalgia rheumatica (PMR), rheumatoid arthritis (RA) and Crohn's disease (2 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Plasma Concentration up to 58 days, Time to Maximum Observed Plasma Concentration up to 58 days and 4 more. Started Oct 2022; status: completed.
02
Drugs
ABBV-154
03
Conditions
polymyalgia rheumatica (PMR)rheumatoid arthritis (RA)Crohn's disease
Beyond the preview
Go deeper on NCT05556226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05556226.